

Menelas N Pangalos

Professional Experience

AstraZeneca, 2019 – present

Executive Vice President and President, BioPharmaceuticals R&D

Cambridge, UK

AstraZeneca, 2016 – 2018

Executive Vice President, Innovative Medicines and Early Development, Worldwide Head Business Development

Cambridge, UK

AstraZeneca, 2010 – 2015

Executive Vice President, Innovative Medicines and Early Development, Worldwide Head Business Development

Cambridge, UK

Kings College London, Wolfson Centre for Age-Related Diseases

Visiting Professor of Neuroscience from 2005 to 2015

Penn University, Institute of Neurological Sciences

Adjunct Professor of Neuroscience from 2007 to 2010

- Accountable for delivery of portfolio from target ideation to product approval – 2019-present
- Accountable for ~6400 individuals across Research and Development, across forty sites globally and an annual budget of \$4bn – 2019-present
- Accountable for delivery of portfolio from target ideation to end of Phase 2 – 2010-2018
- Accountable for ~2500 individuals across Research and Early Development, across four sites in Macclesfield, Cambridge, Gothenburg, Boston and an annual budget of \$1bn – 2010-2018
- Accountable for in-licensing and out-licensing activities across AstraZeneca - 2010-2018
- Chair of Early Stage Portfolio Committee - 2010-present
- Member AZ Senior Executive Team – 2012-present
- Executive Chair AZ Board Science Committee - 2012-present
- Executive sponsor for UK site footprint – AZ move to Cambridge - 2013-present
- External appointments and committees held or previously held
 - Chair of Innovation and Data Expert Group for Life Sciences Industrial Strategy with Lord Henley - 2018
 - Board member of the Life Sciences Industrial Strategy Implementation Board - 2018
 - Board member MRC Council and Remuneration Committee – 2012-current
 - Board member Judge Business School Cambridge University – 2017 -current
 - Board member National Genomics Board – 2017-current
 - Board member Dizal Pharma - 2018
 - Board member British Pharmaceutical Group – 2010-current
 - Board member of National Centre for Universities and Business Council – 2014-current
 - Member of Ministers and Industry Strategy Group – ad hoc member 2013-2017
 - Non-Executive Director Precision Medicine Catapult – 2016-2017
 - Member of ABPI Board – 2014-2015

Pfizer, Dec 2009 – March 2010

Senior Vice President and CSO Neuroscience Research

Groton, CT

- Responsible for 200+ scientists and clinicians taking Pfizer neuroscience programs from target identification through to Proof of Concept

Wyeth Research, Nov 2008 to Nov 2009

Executive Vice President and Head of Discovery Research

Collegeville, PA, USA

- Responsible for 1100+ scientific and operational staff working across Wyeth's core therapeutic areas (CNS, Inflammation, Oncology, Metabolic, Musculoskeletal) with approximately \$350 M yearly operating budget

- Responsible all research and technology platforms, including biology, chemistry, structural biology, protein therapeutics, genomics, systems biology, translational medicine
- Leader of scientific strategy, quality and review and driver of strategic talent management
- Accountable for short and long-term business plans for Research to the Head of R&D and CEO

Wyeth Research, March 2003 to Nov 2008

Vice President and Head of Neuroscience Research

Princeton, NJ, USA

- Responsible for department of 160+ neuroscientists working in the areas of depression, schizophrenia, pain, Alzheimer's disease, Parkinson's disease and stroke with approximately a \$40 M operating budget
- Responsible for the strategic and operational success of Wyeth Neuroscience - target identification to drug candidate selection
- Chair of Neuroscience Therapeutic Area Leadership team and Neuroscience Research Council – accountable for effectively delivering a sustainable CNS pipeline and strategy, all in-licensing activities and early clinical development of the CNS portfolio

GlaxoSmithKline, Dec 1998 to Feb 2003

Group Director and Head of Neurodegeneration Research, March 2001 to Feb 2003

Harlow, UK

- Responsible for running a department of 30 permanent and 10-15 temporary staff
- Responsible for the review, focus, strategic planning and progress of all projects related to neurodegeneration research
- Member of the neurology executive management team

SmithKline Beecham,

Assistant Director Molecular Neuropharmacology, May 2000 to March 2001

Team Leader Molecular Neuropharmacology, Dec 1998 to May 2000

Janssen Pharmaceutica (J&J), Aug 1996 to Nov 1998.

Group Leader, Applied Molecular Biology

Beerse, Belgium.

Bristol Myers Squibb, Aug 1995 to June 1996.

Post-Doctoral Scientist, CNS Drug Discovery,

Connecticut, US

Mount Sinai Medical Center, March 1992 to May 1995.

Visiting Research Fellow

Prof. N.K. Robakis' Laboratory, New York, US

Full Time Education

Graduate, Sep 1988 to Jan 1992

PhD. in Neurochemistry

Prof. D.M. Bowen's Laboratory, Institute of Neurology, University of London

Undergraduate, Sep 1985 to June 1988

First Class (Honors) Degree in Biochemistry

Imperial College of Science and Technology, University of London

Honorary Awards, Recognition and Appointments

Dr Pangalos serves on several Boards including the Council of the Medical Research Council, co-chairs the UK Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board. He is also on the Boards of The Francis Crick Institute, The Judge Business School, Cambridge University and Dizal Pharma.

- 2020 Knighthood by Her Majesty The Queen for services to UK science
- 2019 Galien Scientific Research Award by Prix Galien Greece
- 2019 Honorary Doctorate from Imperial College

- 2018 Pharma Intelligence Clinical & Research Excellence Marquee Award for R&D excellence based on outstanding achievement across various performance metrics that indicate commitment, innovation, operational excellence, and success in bringing new medicines to patients
- 2017 Honorary Doctorate from Glasgow University
- 2017 Scrip Award - Community Partnership of the Year for AstraZeneca's Active Science Program
- 2016 Scrip Award - Best Partnership Alliance for AstraZeneca's Genomics Initiative partnering with Human Longevity
- 2015 Fellow of Clare Hall, University of Cambridge
- 2015 Fellow of the Academy of Medical Sciences
- 2015 Scrip Award - Licencing Deal of the Year acquisition of Almirall in respiratory disease
- 2014 Scrip Award - Licencing Deal of the Year acquisition of Bristol Myers Squibb diabetes alliance
- 2013 Scrip Award - Licencing Deal of the Year with Horizon Discovery for the development and commercialisation of the HD-001 kinase target programme for multiple cancers
- 2013 Scrip Award - Best Partnership Alliance with Bristol Myers Squibb and Amylin in diabetes
- 2012 Fellow of the Royal Society of Biology
- 2012 Scrip Award - Best Partnership Alliance with MRC-AZ Open Innovation Translational Medicine Alliance
- 2008 Recognized as one of six most notable people in R&D by R&D Directions
- 2008 New York Academy of Sciences - Finalist and winner of Innovation in Industry Young Scientists Award
- 2007 R&D Directions - Pharma CNS Pipeline of the Year
- 2007-2010 Adjunct Professor of Neuroscience at Penn University, Institute of Neurological Sciences.
- 2006 Scrip Award - Collaboration of the year - ANRG
- 2006 Scrip Award - R&D management team of the year
- 2005 – present Visiting Professor of Neuroscience at Kings College London